Reata Pharmaceuticals Inc.

43.39+2.53+6.19%Vol 652.52K1Y Perf 69.40%
Jan 27th, 2023 16:00 DELAYED
BID39.99 ASK44.00
Open40.81 Previous Close40.86
Pre-Market- After-Market43.39
 - -  - -%
Target Price
61.10 
Analyst Rating
Strong Buy 1.40
Potential %
40.82 
Finscreener Ranking
     42.08
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     38.54
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+     29.90
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
87.65 
Earnings Rating
Sell
Market Cap1.59B 
Earnings Date
27th Feb 2023
Alpha0.02 Standard Deviation0.30
Beta1.14 

Today's Price Range

40.8143.77

52W Range

18.4746.90

5 Year PE Ratio Range

-64.30-20.90

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
11.69%
1 Month
23.90%
3 Months
45.51%
6 Months
44.39%
1 Year
69.40%
3 Years
-77.68%
5 Years
44.87%
10 Years
-

TickerPriceChg.Chg.%
RETA43.392.53006.19
AAPL145.931.97001.37
GOOG100.711.55001.56
MSFT248.150.15000.06
XOM115.61-2.1500-1.83
WFC46.120.31000.68
JNJ168.23-0.6600-0.39
FB196.640.99000.51
GE83.232.09002.58
JPM140.320.34000.24
 
ProfitabilityValueIndustryS&P 500US Markets
100.00
-8 482.20
-8 444.90
-2 693.60
-
RevenueValueIndustryS&P 500US Markets
2.22M
0.07
-28.18
-30.57
Earnings HistoryEstimateReportedSurprise %
Q03 2022-2.35-2.168.09
Q02 2022-1.90-2.02-6.32
Q01 2022-2.26-2.0310.18
Q04 2021-2.31-2.35-1.73
Q03 2021-2.32-1.9715.09
Q02 2021-2.13-2.006.10
Q01 2021-2.18-1.8614.68
Q04 2020-2.14-1.9011.22
Earnings Per EndEstimateRevision %Trend
12/2022 QR-2.12-8.72Negative
12/2022 FY-8.38-0.12Negative
3/2023 QR-2.17-7.43Negative
12/2023 FY-8.092.65Positive
Next Report Date27th Feb 2023
Estimated EPS Next Report-2.12
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume652.52K
Shares Outstanding36.64K
Shares Float20.30M
Trades Count12.09K
Dollar Volume27.94M
Avg. Volume724.75K
Avg. Weekly Volume999.22K
Avg. Monthly Volume594.87K
Avg. Quarterly Volume580.15K

Reata Pharmaceuticals Inc. (NASDAQ: RETA) stock closed at 43.39 per share at the end of the most recent trading day (a 6.19% change compared to the prior day closing price) with a volume of 652.52K shares and market capitalization of 1.59B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 220 people. Reata Pharmaceuticals Inc. CEO is J. Warren Huff.

The one-year performance of Reata Pharmaceuticals Inc. stock is 69.4%, while year-to-date (YTD) performance is 14.21%. RETA stock has a five-year performance of 44.87%. Its 52-week range is between 18.47 and 46.9, which gives RETA stock a 52-week price range ratio of 87.65%

Reata Pharmaceuticals Inc. currently has a PE ratio of -4.10, a price-to-book (PB) ratio of 285.94, a price-to-sale (PS) ratio of 544.11, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -51.81%, a ROC of -105.23% and a ROE of -281.69%. The company’s profit margin is -%, its EBITDA margin is -8 444.90%, and its revenue ttm is $2.22 Million , which makes it $0.07 revenue per share.

Of the last four earnings reports from Reata Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-2.12 for the next earnings report. Reata Pharmaceuticals Inc.’s next earnings report date is 27th Feb 2023.

The consensus rating of Wall Street analysts for Reata Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $61.1, which is +40.82% compared to the current price. The earnings rating for Reata Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Reata Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Reata Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 6.44, ATR14 : 2.89, CCI20 : 148.79, Chaikin Money Flow : -0.12, MACD : 1.48, Money Flow Index : 66.66, ROC : 12.70, RSI : 66.68, STOCH (14,3) : 70.15, STOCH RSI : 1.00, UO : 49.18, Williams %R : -29.85), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Reata Pharmaceuticals Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
8 (80.00 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (20.00 %)
2 (20.00 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.44

Reata Pharmaceuticals Inc.

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

CEO: J. Warren Huff

Telephone: +1 972 865-2219

Address: 5320 Legacy Drive, Plano 75024, TX, US

Number of employees: 220

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

56%44%

Bearish Bullish

65%35%

Bearish Bullish

59%41%

TipRanks News for RETA


News

Stocktwits